On August 10, Vertex Pharmaceuticals rose 3.26% in pre-market trading, trading at $515.0/share, with turnover of $419,400.

The move follows the company's Q2 earnings release, which showed revenue of $3.33 billion, surpassing the consensus estimate of $3.23 billion and representing a 12.5% year-over-year increase. Adjusted EPS came in at $4.73, up 4.6% from the prior year. The company also raised its full-year revenue guidance to $13.1 billion-$13.2 billion, above the prior range of $12.95 billion-$13.1 billion and the FactSet consensus of $13.06 billion.

Following the results, multiple institutions raised their price targets: Cantor Fitzgerald adjusted to $595, Goldman Sachs maintained Buy with a $652 target, and RBC Capital highlighted unrecognized pipeline upside in kidney programs and chronic pain. Additionally, the $10 billion acquisition of Crinetics Pharmaceuticals is expected to close this quarter, adding a fifth business pillar in endocrinology with approximately $5 billion in peak sales potential.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)